依库珠单抗与 aHUS：用还是不用。
Eculizumab and aHUS: to stop or not.
机构信息
Johns Hopkins University.
出版信息
Blood. 2021 May 6;137(18):2419-2420. doi: 10.1182/blood.2020010234.
Abstract
In this issue of , Fakhouri et al provide evidence in a prospective phase 4, multicentric, noncontrolled study that discontinuing eculizumab is safe in most patients with atypical hemolytic uremic syndrome (aHUS) once they achieve complete remission. Risk of relapse was <25% overall, but as high as 50% in patients with a rare variant in at least 1 complement gene.
摘要
本期 中，Fakhouri 等人提供了一项前瞻性、多中心、非对照研究的证据，表明大多数非典型溶血性尿毒症综合征（aHUS）患者在完全缓解后停用依库珠单抗是安全的。总体复发风险<25%，但至少有 1 种补体基因突变的罕见变异患者复发风险高达 50%。
相似文献
1
Eculizumab and aHUS: to stop or not.依库珠单抗与 aHUS：用还是不用。
Blood. 2021 May 6;137(18):2419-2420. doi: 10.1182/blood.2020010234.
2
[Atypical hemolytic uremic syndrome with C3 p.I1157T missense mutation successfully treated with eculizumab].[伴有C3 p.I1157T错义突变的非典型溶血尿毒综合征经依库珠单抗成功治疗]
Rinsho Ketsueki. 2018;59(2):178-181. doi: 10.11406/rinketsu.59.178.
3
Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.依库珠单抗在日本成人非典型溶血性尿毒症综合征患者中的安全性和有效性：上市后监测的中期分析
Clin Exp Nephrol. 2019 Jan;23(1):65-75. doi: 10.1007/s10157-018-1609-8. Epub 2018 Jun 29.
4
Efficacy and safety of eculizumab in adult patients with atypical hemolytic uremic syndrome: A single center experience from Turkey.依库珠单抗治疗非典型溶血性尿毒症综合征成年患者的疗效与安全性：来自土耳其的单中心经验
Transfus Apher Sci. 2016 Dec;55(3):357-362. doi: 10.1016/j.transci.2016.09.017. Epub 2016 Sep 30.
5
Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.依库珠单抗在日本儿童非典型溶血性尿毒症综合征患者中的安全性和有效性：上市后监测的中期分析
Clin Exp Nephrol. 2019 Jan;23(1):112-121. doi: 10.1007/s10157-018-1610-2. Epub 2018 Jul 23.
6
Successful 7-Year Eculizumab Treatment of Plasmapheresis-Resistant Recurrent Atypical Hemolytic-Uremic Syndrome due to Complement Factor H Hybrid Gene: A Case Report.补体因子H杂交基因所致血浆置换抵抗性复发性非典型溶血尿毒综合征的依库珠单抗成功治疗7年：病例报告
Transplant Proc. 2018 Apr;50(3):967-970. doi: 10.1016/j.transproceed.2018.02.012.
7
Adult Post-Kidney Transplant Familial Atypical Hemolytic Uremic Syndrome Successfully Treated With Eculizumab: A Case Report and Literature Review.依库珠单抗成功治疗成人肾移植后家族性非典型溶血性尿毒症综合征：一例报告及文献综述
Am J Ther. 2016 Jul-Aug;23(4):e1110-5. doi: 10.1097/MJT.0000000000000133.
8
Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T Mutation.一例伴有补体C3 I1157T突变的非典型溶血性尿毒症综合征患者早期停用依库珠单抗后的疾病复发
J Pediatr Hematol Oncol. 2016 Apr;38(3):e137-9. doi: 10.1097/MPH.0000000000000505.
9
Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.非典型溶血性尿毒症综合征：病例报告的荟萃分析证实基因突变的患病率及治疗方案的转变
Ther Apher Dial. 2018 Apr;22(2):178-188. doi: 10.1111/1744-9987.12641. Epub 2017 Dec 17.
10
Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.依库珠单抗治疗与儿童中高突变相关非典型溶血尿毒综合征的肾脏改善恢复：一项回顾性队列研究。
Kidney Blood Press Res. 2020;45(6):939-954. doi: 10.1159/000510612. Epub 2020 Nov 25.
引用本文的文献
1
Real-World effectiveness of eculizumab in atypical hemolytic uremic syndrome: a retrospective study from Western China.依库珠单抗治疗非典型溶血性尿毒症综合征的真实世界疗效：一项来自中国西部的回顾性研究。
Front Endocrinol (Lausanne). 2025 Jun 27;16:1568082. doi: 10.3389/fendo.2025.1568082. eCollection 2025.
2
Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database.基于FARES数据库的依库珠单抗相关药品不良事件（ADEs）风险信号挖掘
Front Pharmacol. 2025 Jan 9;15:1440907. doi: 10.3389/fphar.2024.1440907. eCollection 2024.
3
A Rare Case of Atypical Hemolytic Uremic Syndrome (aHUS) Precipitated by Dengue and the Treatment Landscape in Singapore.一例由登革热引发的非典型溶血尿毒综合征（aHUS）罕见病例及新加坡的治疗情况
Cureus. 2024 Apr 22;16(4):e58731. doi: 10.7759/cureus.58731. eCollection 2024 Apr.
4
Neurological involvement in hematopoietic stem cell transplantation-associated thrombotic microangiopathy.造血干细胞移植相关性血栓性微血管病的神经学表现。
Ann Hematol. 2024 Sep;103(9):3303-3313. doi: 10.1007/s00277-024-05798-6. Epub 2024 May 20.
5
The Production of Complement Inhibitor Proteins in Mammalian Cell Lines-Light at the End of the Tunnel?哺乳动物细胞系中补体抑制蛋白的生产——曙光在前？
Biomedicines. 2024 Mar 14;12(3):646. doi: 10.3390/biomedicines12030646.
6
Atypical Hemolytic Uremic Syndrome: A Nationwide Colombian Pediatric Series.非典型溶血性尿毒症综合征：一项哥伦比亚全国性儿科研究系列
Glob Pediatr Health. 2024 Feb 10;11:2333794X241231133. doi: 10.1177/2333794X241231133. eCollection 2024.
7
Rational use of eculizumab in secondary atypical hemolytic uremic syndrome.依库珠单抗在继发性非典型溶血性尿毒症综合征中的合理应用。
Front Immunol. 2024 Jan 11;14:1310469. doi: 10.3389/fimmu.2023.1310469. eCollection 2023.
8
Complement-mediated thrombotic microangiopathy treated with anticomplement protein 5 therapy, a retrospective study.补体介导的血栓性微血管病经抗补体蛋白 5 治疗的回顾性研究。
Eur J Haematol. 2024 Mar;112(3):450-457. doi: 10.1111/ejh.14136. Epub 2023 Nov 20.
9
Underlying Genetics of aHUS: Which Connection with Outcome and Treatment Discontinuation?aHUS 的潜在遗传学：与结局和治疗停药的关联是什么？
Int J Mol Sci. 2023 Sep 24;24(19):14496. doi: 10.3390/ijms241914496.
10
New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses.依库珠单抗治疗肾移植后抗血友病因子相关血管性血友病患者预防复发和改善肾功能的新发现：系统评价和荟萃分析。
Ren Fail. 2023 Dec;45(1):2231264. doi: 10.1080/0886022X.2023.2231264.
本文引用的文献
1
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.长效 C5 抑制剂 ravulizumab 对补体抑制剂治疗初治的儿童非典型溶血尿毒症综合征患者有效且安全。
Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8.
2
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.儿童和成人非典型溶血性尿毒综合征中依库珠单抗的停药：一项前瞻性多中心研究。
Blood. 2021 May 6;137(18):2438-2449. doi: 10.1182/blood.2020009280.
3
Complementopathies and precision medicine.补体系统相关疾病与精准医学
J Clin Invest. 2020 May 1;130(5):2152-2163. doi: 10.1172/JCI136094.
4
Eculizumab cessation in atypical hemolytic uremic syndrome.非典型溶血性尿毒症综合征中依库珠单抗的停药
Blood. 2017 Jul 20;130(3):368-372. doi: 10.1182/blood-2017-02-770214. Epub 2017 May 1.
5
Haemolytic uraemic syndrome.溶血尿毒综合征。
Lancet. 2017 Aug 12;390(10095):681-696. doi: 10.1016/S0140-6736(17)30062-4. Epub 2017 Feb 25.
6
Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation.补体基因中的致病性变异与依库珠单抗停药后非典型溶血尿毒症综合征复发的风险。
Clin J Am Soc Nephrol. 2017 Jan 6;12(1):50-59. doi: 10.2215/CJN.06440616. Epub 2016 Oct 31.
7
Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update.非典型溶血性尿毒症综合征中依库珠单抗治疗的停药：最新进展
Am J Kidney Dis. 2015 Jul;66(1):172-3. doi: 10.1053/j.ajkd.2015.04.010.
8
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.依库珠单抗治疗非典型溶血尿毒综合征。
N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.
9
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.用于治疗阵发性夜间血红蛋白尿的补体抑制剂依库珠单抗的发现与研发。
Nat Biotechnol. 2007 Nov;25(11):1256-64. doi: 10.1038/nbt1344.
Zotero 插件